Shenzhen Beimei Pharmaceutical Co., Ltd. is an enterprise specializing in the development, introduction and sales of pediatric medicines. Product development strategies include independent research and development and the introduction of excellent foreign pediatric products. The company focuses on pediatric chemical prescription medicines and with an efficient BD team to solve the problem of domestic pediatric medicine accessibility and compliance. It conducts project research and introduction in combination with clinical and market conditions. The approved products and services are competitive to meet the domestic clinical urgent and unmet medical needs, have broad market prospects. Through entrusted R&D, import product license, independent R&D and other models, we have successively developed more than ten generic products projects, forming a strong pediatric chemical prescription medicine development capability.
Our company's R&D center for pediatric medicines was established in Longhua Yifenghua Industrial Park, put into use at the end of April 2020. Based on the clinical application characteristics of pediatric medicines, it is planned to independently develop top preparation technologies and products for the treatment of common childhood diseases such as infection, epilepsy, hyperactivity, and allergies, including inhalation, nasal spray, dry suspension, oral solution and other dosage forms. From the perspective of improving the compliance of pediatric medicines, we develop new prescription masking technologies with independent intellectual property rights, mixed granulation and other prescription process technologies to form a strong research and development capability for top pediatric prescription medicines to meet the domestic clinical needs.
Our company has established good cooperative relations with scientific research institutions such as China Pharmaceutical University, Guangzhou Renheng Pharmaceutical Technology Co., Ltd. and other R&D CRO companies. We cooperate in prescription development and quality research, such as BM_R03_TM and other pediatric medicines.
At the same time, our company has established good cooperative relations with several drug manufacturing enterprises in Shandong, Sichuan, Guangdong and other places. Our company has launched the entrusted production cooperation of products in research under the framework of the MAH (Marketing Authorization Holder) system. And has planned quality assurance and pharmacovigilance system covering the entire life cycle of the medicine, fulfill the main responsibility of the MAH.
